EyePoint Pharmaceuticals Inc. (EYPT) Insider Trading

Last 12 months

Insiders bought $72k and sold $1.1M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$1.03M

2 buys · 8 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

2 / 2

executives and directors

Last open-market buy

Aug 2026

Aug 18, 2026

Get an email when EYPT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 18	Karen L. Zaderej Director	Bought	10,600	$4.93	$52k	28%	Form 4
Jun 30	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan 2 parts	4,875	$15.01 average	$73k	100%	Form 4
Apr 17	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan	2,437	$15.00	$37k	100%	Form 4
Mar 16	Jay S. Duker President and CEO	Bought	1,500	$13.15	$20k	0.8%	Form 4
Mar 4	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan	2,438	$17.87	$44k	100%	Form 4
Feb 17	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan	2,437	$15.00	$37k	100%	Form 4
Jan 5	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan	42,544	$17.10	$728k	100%	Form 4
Dec 4, 2025	Cormorant Asset Management, LP Large holder	SoldNo plan	60,000	$15.70	$942k	0.7%	Form 4
Dec 4, 2025	Nancy Lurker Director	Sold10b5-1 plan	9,300	$15.11	$141k	2.7%	Form 4
Nov 26, 2025 – Nov 28, 2025	Nancy Lurker Director	Sold10b5-1 plan 2 parts	700	$14.95 average	$10k	0.2%	Form 4
Nov 11, 2025	Ramiro Ribeiro Chief Medical Officer	Sold10b5-1 plan	2,722	$11.61	$32k	100%	Form 4
May 16, 2025 – May 19, 2025	Karen L. Zaderej Director	Bought 2 parts	10,000	$5.90 average	$59k	38%	Form 4
May 14, 2025 – May 15, 2025	Karen L. Zaderej Director	Bought 2 parts	10,000	$5.45 average	$54k	61%	Form 4

Aug 18
Karen L. Zaderej
Director · bought 10,600 at $4.93
$52k
28% of stake
Jun 3010b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 4,875 at avg $15.01
$73k
100% of stake
Apr 1710b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 2,437 at $15.00
$37k
100% of stake
Mar 16
Jay S. Duker
President and CEO · bought 1,500 at $13.15
$20k
0.8% of stake
Mar 410b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 2,438 at $17.87
$44k
100% of stake
Feb 1710b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 2,437 at $15.00
$37k
100% of stake
Jan 510b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 42,544 at $17.10
$728k
100% of stake
Dec 4, 2025No plan
Cormorant Asset Management, LP
Large holder · sold 60,000 at $15.70
$942k
0.7% of stake
Dec 4, 202510b5-1 plan
Nancy Lurker
Director · sold 9,300 at $15.11
$141k
2.7% of stake
Nov 26, 2025 – Nov 28, 202510b5-1 plan
Nancy Lurker
Director · sold 700 at avg $14.95
$10k
0.2% of stake
Nov 11, 202510b5-1 plan
Ramiro Ribeiro
Chief Medical Officer · sold 2,722 at $11.61
$32k
100% of stake
May 16, 2025 – May 19, 2025
Karen L. Zaderej
Director · bought 10,000 at avg $5.90
$59k
38% of stake
May 14, 2025 – May 15, 2025
Karen L. Zaderej
Director · bought 10,000 at avg $5.45
$54k
61% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EYPT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Laboratory Analytical Instruments

ASTCAstrotech Corporation

SCNDScientific Industries Inc.

LCTCLifeloc Technologies Inc.

SEERSeer, Inc.

PRPOPrecipio Inc.

UCLEUs Nuclear Corp.

RSCFReflect Scientific Inc.

QSIQuantum-Si Incorporated

Spot a number that looks wrong? Check it in EYPT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EYPT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.